We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
25 Jun 2026 - 27 Jun 2026
08 Jul 2026 - 10 Jul 2026

Alliance to Recover Leukocytes for Therapeutic Use

By HospiMedica staff writers
Posted on 15 Feb 2001
An alliance to recover leukocytes has been entered into by Pall Corp. More...
(East Hills, NY, USA) and Viragen, Inc. (Plantation, FL, USA). Pall will grant an exclusive (except for Japan) worldwide license to proprietary technology that will enable Viragen to efficiently remove and recover leukocytes from leukoreduction filters. The goal is to provide additional sources of leukocytes for Viragen's production of interferons for therapeutic use.

Viragen's lead product, Omniferon, a multisubtype alpha interferon, is currently in phase II clinical trials for the treatment of hepatitis C. Omniferon is derived from white blood cells using Viragen's unique manufacturing technology. Viragen has white blood cell sourcing agreements with other blood organizations, including the American Red Cross and the German Red Cross.

"Blood centers normally discard blood filters after each use,” noted Gerald Smith, chairman and CEO of Viragen. "The potential access to all filtered white blood cells increases Viragen's capability to maximize production of Omniferon.”

Pall is a leader in the filtrations and separations industry, supplying products for use in transfusion medicine, biopharmaceuticals, and in other industries. Pall blood filters are used in all 10 countries that have mandated universal leukocyte reduction.



Related Links:
Pall
Viragen

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Monitor/Defibrillator
Zenix
Wound Irrigation Solution
Prontosan®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Coredio’s CPSE is a a software-as-a-medical-device platform designed for use with consumer smartwatches and standard blood pressure cuffs in clinical and home settings under physician supervision (Photo courtesy of Coredio)

AI Platform Supports Noninvasive Remote Hemodynamic Monitoring in Heart Failure

Heart failure remains a leading cause of hospitalization in adults over 65, affecting more than 6.7 million people in the U.S. Clinicians often lose visibility into hemodynamic deterioration once patients... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.